Diabetes Mellitus and Lipid Dysregulation

Diabetes mellitus (DM) induces hyperglycemia due to insulin shortage or malfunction [1]. One of the most common endocrine illnesses globally, its long-term vascular repercussions cause significant morbidity and mortality. Diabetic dyslipidaemia impairs lipid metabolism. This condition causes atherosclerosis and CVD, the major diabetes killer. In diabetes, higher LDL-C, TG and lower HDL-C indicate dysregulated lipid metabolism [2,3]. Endothelial dysfunction, plaque development, stroke, and coronary artery disease depend on this lipid triad.

Mechanisms of Altered Lipid Metabolism

Several insulin resistance-related pathways cause diabetes lipid abnormalities [4]. In healthy adults, insulin increases adipose tissue lipogenesis and decreases lipolysis. Type 2 diabetes and other insulin-resistant illnesses release Free Fatty Acids (FFA) from adipose tissue into the circulation [5]. The liver absorbs free fatty acids and raises VLDL and triglycerides. Triglyceride clearance decreases with lower lipoprotein lipase (LPL) activity, exacerbating hypertriglyceridemia [6].

Microscopically dense, atherogenic LDL particles are common in diabetics [7]. Oxidized particles can form atherosclerotic plaques in artery walls. Diabetes increases HDL particle catabolism and triglyceride exchange, lowering HDL-C [8]. These lipid abnormalities affect lipid homeostasis and increase oxidative stress and inflammation, creating a pro-atherogenic environment.

Cardiovascular Implications

Diabetes affects lipids and cardiovascular health [9,10]. Diabetics are two to four times more likely to have CVD, according to epidemiology. Endothelial dysfunction, inflammation, and thrombogenesis of dyslipidemia produce microvascular and macrovascular problems [11]. High triglycerides and LDL-C make plaque more unstable, while low HDL-C hinders reverse cholesterol transfer, which destroys arteries [12]. Atherogenesis is worsened by oxidized LDL and apolipoprotein glycation in diabetics. Diabetes patients' lipid metabolism must be understood to prevent cardiovascular problems early.

Rationale for the Present Study

Cardiovascular problems remain a major issue worldwide despite improved diabetes control. Lifestyle, nutritional, and genetic changes worsen it. Population dyslipidaemia and cardiovascular risk can be revealed by diabetic lipid metabolism. In our study we examined diabetes patients' lipid levels for cardiovascular disease risk from June 2023 – June2025.

Objectives

·          To Assess lipid metabolism changes in diabetes patients, concentrating on critical parameters such total cholesterol, triglycerides, HDL-C, and LDL-C levels.

·          To Examine the link between lipid abnormalities and cardiovascular risk factors in diabetic patients presenting to the Internal Medicine Clinic.

·          To Evaluate the impact of diabetic dyslipidaemia on cardiovascular disease and identify early prevention and therapy opportunities.

A Retrospective observational study examined how lipid metabolism influences cardiovascular risk in many diabetics. Internal Medicine Department, Prime Specialist Medical Centre conducted a 2 year-long study from June 2023 to June 2025. Clinical, biochemical, and demographic data from diabetic patients' medical records were studied. The study examined diabetic dyslipidaemia patterns and cardiovascular risk.

Study Population and Setting

100 individuals with type 1 as well as type 2 diabetes who attended the Internal Medicine department were studied. Electronic medical records data was used. The study population was multiethnic and  heterogeneous. To examine metabolic-clinical relationships, age, gender, diabetes duration, BMI, blood pressure, and cardiovascular disease history were gathered.

Inclusion criteria

1.        Patients aged 18 years and above diagnosed with diabetes mellitus (type 1 or type 2).

2.        Patients with complete records of fasting lipid profile and glycaemic control parameters (HbA1c, fasting glucose).

3.        Patients with a minimum of one year of diabetes duration to ensure metabolic stabilization.

Exclusion criteria

1.        Patients with secondary causes of dyslipidaemia such as chronic liver disease, hypothyroidism, or nephrotic syndrome.

2.        Patients on lipid-lowering therapy prior to data collection.

3.        Pregnant or lactating women.

4.        Patients with incomplete or missing laboratory data.

Data Collection and Biochemical Parameters

Data from patient records were retrospectively obtained using a standard form. Important biochemical parameters were evaluated using enzymatic colorimetric assays after a 12-hour fast. The parameters are TC, TG, LDL-C, HDL-C, HbA1c, FBG, BMI, and blood pressure. Cardiovascular risk was assessed using lipid profiles and hypertension or cardiovascular disease history.

Statistical Analysis

Data was compiled and analysed using SPSS. Biochemical and demographic data were condensed using averages, standard deviations, and percentages. Chi-square tests and Pearson's correlation were used to assess lipid parameters and cardiovascular risk indicators. To compare subgroup lipid levels, we employed independent t-tests or ANOVA. A p-value below 0.05 indicated statistical significance.

Demographic Profile of Patients

This retrospective analysis included 100 diabetics. The study population had a mean age of 54.8 ± 10.6 years, with 56% males and 44% females. Patients aged 50–60 comprised the majority. The average duration of diabetes was 8.3 ± 4.2 years. The majority of patients were overweight or obese, with an average BMI of 28.6 ± 3.9 kg/m². Cardiovascular disease (CVD), including coronary artery disease and ischemic heart disease, was present in 32% of patients, and 64% had concomitant hypertension.

Table 1 Demographic of the Study Population

The results showed that this group of diabetics was middle-aged or older, overweight, and had the condition for a long time with poor glycaemic control (HbA1c > 8%). The high prevalence of hypertension and cardiovascular illness in this population emphasizes the need of researching lipid abnormalities as a risk factor for cardiovascular disease.

Lipid Parameters in Diabetic Patients

The average lipid parameters were found: TC = 208.7 ± 42.6 mg/dL, TG = 189.4 ± 56.3, LDL-C = 132.5 ± 35.2, and HDL-C = 38.2 ± 7.5 mg/dL. Approximately 68% of patients had elevated LDL-C levels (>130 mg/dL), 72% had hypertriglyceridemia (>150 mg/dL), and 74% had low HDL-C levels (<40 mg/dL).

Table 2 Lipid Profile of Diabetic Patients

Diabetic dyslipidemia is indicated by high triglycerides, LDL-C, and low HDL-C. The lipid triad's atherogenicity puts diabetics at risk for cardiovascular disease. This group's high lipid profile abnormality rate indicates poor glucose management and insulin resistance.

Correlation between Lipid Profile and Cardiovascular Risk

LDL-C and cardiovascular disease were strongly connected (r = 0.46, p < 0.01), while triglycerides as well as BMI were negatively correlated (r = 0.39, p < 0.05). A significant negative connection (r = -0.41, p < 0.01) exists between decreased HDL-C levels and increased risk of cardiovascular disease.

Table 3 Correlation between Lipid Parameters and Cardiovascular Risk Factors

Dyslipidemia, particularly high LDL-C and triglycerides and lower HDL-C, substantially corresponds with cardiovascular risk factors in diabetics. Higher BMI and hypertension caused worse lipid abnormalities. It appears that diabetes-related lipid metabolic disorders significantly enhance cardiovascular morbidity and mortality.

These findings underscore the significance of routine cholesterol monitoring and aggressive dyslipidaemia treatment in diabetics to prevent cardiovascular disease.

This retrospective study assessed 100 diabetes patients' lipids and CVD risk. Diabetes raised triglycerides, LDL-C, and low HDL-C. Hypertriglyceridemia affected 72% of patients, raising LDL-C 68%, lowering HDL-C 74%, and raising total cholesterol 50%. These findings support past studies in comparable groups that revealed poorly controlled diabetes was associated with mixed dyslipidaemia.

Poor metabolic control and obesity worsen lipid abnormalities, according to the study, which also identified a substantial positive correlation between LDL-C and cardiovascular disease and triglycerides and BMI. Supporting the prevention of atherosclerosis, HDL-C was negatively connected to cardiovascular disease. Since most participants had hyperglycemia and hypertension, which increase cardiovascular risk, multifactorial therapy is essential for long-term success. The data reveal that diabetics' cardiovascular risk profile includes lipid abnormalities, not metabolic problems.

Table 4 Comparison of the Present Study with Previous Research on Lipid Metabolism in Diabetes

Pathophysiological Mechanisms

This study's lipid abnormalities are caused by insulin resistance, altered hepatic lipid metabolism, and decreased lipoprotein clearance. In diabetes, especially type 2, insulin resistance reduces insulin's inhibitory effect on adipose tissue lipolysis. FFAs are released into the bloodstream by overproduction and absorbed by the liver. Higher levels of FFA in the liver raise triglycerides and VLDL.

Reduced lipoprotein lipase activity reduces the breakdown of circulating triglycerides, causing persistent hypertriglyceridemia. High VLDL levels make cholesterol more easily transferred from HDL to LDL, making LDL more vulnerable to oxidation and endothelial uptake and speeding atherogenesis. The reverse cholesterol transport and antioxidant defense systems are further weakened by decreased HDL-C. Diabetes increases the risk of cardiovascular disease due to metabolic abnormalities like arterial inflammation, endothelial dysfunction, and atherosclerotic plaques.

Chronic hyperglycemia causes oxidative stress and lipoprotein glycation, which impairs lipid metabolism. Impaired hepatic receptor clearance of glycated LDL particles increases their circulation-resident residence duration and plaque formation. This study shows that metabolic dysregulation, which causes diabetes, causes lipid abnormalities.

Study Strengths and Limitations

The retrospective analysis of multiethnic diabetes patients data makes this study valuable. Laboratory and correlation analysis produced valid lipid metabolism and cardiovascular risk data. Diabetes management should include metabolic evaluation beyond glucose control, according to the study.

Some factors in the retrospective analysis may have missing data from medical records. The results may not apply to all diabetics due to the limited sample size (n = 100). Dyslipidaemia and cardiovascular outcomes cannot be causally related due to cross-sectional evidence. Food, exercise, and medicine may affect lipid levels. Future prospective trials with larger cohorts and longitudinal follow-up must confirm and evaluate treatment implications.

In this study data of 100 diabetes patients' lipid metabolism and cardiovascular risk from June 2023 to June 2025. Diabetes dyslipidaemia high triglycerides (72%), elevated LDL-C (68%), and decreased HDL-C (74%) was common. Weight, blood pressure, and cardiovascular disease history strongly correlated with these anomalies. These data suggest that lipid dysregulation is a key metabolic issue in diabetes and a CVD risk factor. Dyslipidaemia and poor glycaemic control (mean HbA1c 8.4%) damage arteries, connecting glucose and lipid metabolism. Untreated dyslipidaemia increases diabetics' cardiovascular disease and death risk. Lipid, blood pressure, and glucose monitoring are needed to manage diabetes. Treating lipid abnormalities early reduces myocardial infarction, stroke, and peripheral vascular disease. Controlling glycaemic and lipids with statins, fibrates, and lifestyle changes may improve long-term effects. Clinicians should prioritize cardiovascular risk-based cholesterol control above glucose. Healthy diet, weight loss, and exercise instruction lower metabolic risk factors.

1.        V. G. Athyros, M. Doumas, K. P. Imprialos, K. Stavropoulos, E. Georgianou, A. Katsimardou, and A. Karagiannis, “Diabetes and lipid metabolism,” Hormones, vol. 17, no. 1, pp. 61–67, 2018.

2.        S. Eid, K. M. Sas, S. F. Abcouwer, E. L. Feldman, T. W. Gardner, S. Pennathur, and P. E. Fort, “New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism,” Diabetologia, vol. 62, no. 9, pp. 1539–1549, 2019.

3.        Y. Li, X. Liu, Q. Li, P. Zhou, Q. Chen, B. Jiang, and T. Zhu, “Association of helicobacter pylori infection with lipid metabolism and 10-year cardiovascular risk in diabetes mellitus: A cross-sectional study,” PloS One, vol. 20, no. 4, p. e0319688, 2025.

4.        A. Muscella, E. Stefàno, and S. Marsigliante, “The effects of exercise training on lipid metabolism and coronary heart disease,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 319, no. 1, pp. H76–H88, 2020.

5.        A. M. Mezincescu et al., “Comparison of intramyocellular lipid metabolism in patients with diabetes and male athletes,” Nature Communications, vol. 15, no. 1, p. 3690, 2024.

6.        M. Li and J. Yuan, “Effects of very low-carbohydrate ketogenic diet on lipid metabolism in patients with type II diabetes mellitus: a meta-analysis,” Nutrición Hospitalaria, vol. 39, no. 4, 2022.

7.        S. Badri Al-mhanna et al., “The impact of various types of exercise on lipid metabolism in patients with type 2 diabetes and concurrent overweight/obesity: a narrative review,” Annals of Applied Sport Science, vol. 12, pp. 0–0, 2024.

8.        M. Wysocki et al., “Analysis of changes in glucose and lipid metabolism in patients with clinically severe obesity and type 2 diabetes mellitus undergoing laparoscopic sleeve gastrectomy Prospective observational study,” Obesity Surgery, vol. 34, no. 2, pp. 467–478, 2024.

9.        F. N. U. Jyotsna et al., “Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes,” Cureus, vol. 15, no. 8, 2023.

10.     K. Lu et al., “Effect of viscous soluble dietary fiber on glucose and lipid metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis on randomized clinical trials,” Frontiers in Nutrition, vol. 10, p. 1253312, 2023.

11.     A. Poznyak, A. V. Grechko, P. Poggio, V. A. Myasoedova, V. Alfieri, and A. N. Orekhov, “The diabetes mellitus–atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation,” International Journal of Molecular Sciences, vol. 21, no. 5, p. 1835, 2020.

12.     A. Szlas, J. M. Kurek, and Z. Krejpcio, “The potential of L-arginine in prevention and treatment of disturbed carbohydrate and lipid metabolism—A review,” Nutrients, vol. 14, no. 5, p. 961, 2022.

13.     S. Xing, Y. Xie, Y. Zhang, R. Zhang, D. Zeng, and X. Yue, “Effect of different training modalities on lipid metabolism in patients with type II diabetes mellitus: a network meta-analysis,” Annals of Medicine, vol. 56, no. 1, p. 2428432, 2024.

14.     X. Lv et al., “The effect of tirzepatide on weight, lipid metabolism and blood pressure in overweight/obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis,” Diabetes, Metabolic Syndrome and Obesity, pp. 701–714, 2024.

15.     R. Suarez et al., “Very low calorie ketogenic diet: What effects on lipid metabolism?,” Current Nutrition Reports, vol. 13, no. 3, pp. 516–526, 2024.